ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to evaluate the safety, tolerability, and recommended dose of intr…

Pancreas Cancer, Duct Cell AdenocarcinomaPancreatic CancerAdvanced Pancreatic Adenocarcinoma

~Estimated

~$10 – $8,750

Loki Therapeutics, Inc.NCT07828236

Phase 1

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumor…

Prostate Cancer Castration-resistant Prostate CancerBreast CancerColo-rectal Cancer+2 more

~Estimated

~$10 – $8,750

MBrace TherapeuticsNCT07145255